Navigation Links
Intercell AG: Novel tuberculosis Vaccine Shows Promising,Immunogenicity and Safety Profile

l outcome of the phase I trial has paved the way to move our novel TB vaccine forward. It is designed to function in a stand alone schedule, as well as in combination with previous exposure(s) to BCG or other closely related mycobacteria. It seems that our decision to combine our antigen with IC31™ has been a sound judgement on the base of our preclinical data”, explains Peter Andersen, Director of Vaccine Research and Development, SSI.

Intercell’s CSO, Alexander von Gabain, commented: “Our adjuvant IC31™ proved an outstanding profile to stimulate a strong T-cell immune response in humans as already previously seen in a variety of animal models. These results prove the scientific concept of our adjuvant and encourage a broad and commercial use of IC31™ in a variety of prophylactic and therapeutic vaccines.”

About tuberculosis

TB causes the death of two-three million people every year and one-third of the world’s population is infected by the bacteria Mycobacterium tuberculosis which makes this disease one of the most severe global health problems.

The Calmette (Bacillus Calmette-Guérin (BCG)) vaccine is a live vaccine that, when given to newborns, provides good protection against TB for 10-15 years. However, when the protective effect decreases, yet another BCG vaccination does not provide sufficient TB protection. Therefore, a new type of TB vaccine is needed to address the need of TB protection in the adult population.

About H1

H1 is a TB vaccine antigen in which two immuno dominant TB antigens (Ag85B and ESAT6) are fused together by recombinant technology and produced as a poly-protein.

About IC31TM

Adjuvants enhance the effectiveness of vaccines. Existing adjuvants on the market induce antibod
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
2. Anacor Identifies a Novel Mechanism for Its Lead Anti-Fungal Drug, AN2690; Findings Published in Science
3. Novelos Therapeutics Announces Encouraging Results in Ongoing Phase 2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care
4. Prolexys Pharmaceuticals and Columbia University Researchers Publish Study on Anti-Tumor Properties of a Selective Small Molecule Anti-Tumor Agent With Novel Mechanism of Action
5. Algeta Demonstrates Targeted Cancer-killing Potential of Novel Alpha Particle Linked Antibodies in Leading Medical Journal Blood
6. Novel Mechanism Insights and Additional Data on CombinatoRx Drug Candidates to Be Presented at Upcoming EULAR Meeting
7. Roxro Pharma’s Novel Intranasal Pain Reliever Effective, Well Tolerated in Phase 3 Study
8. Anacor Clinical Study of AN2728, a Novel Anti-Inflammatory Compound, Shows Efficacy in Psoriasis
9. Metabasis Therapeutics Presents Results of Preclinical Studies for MB07811, Its Novel Product Candidate for the Treatment of Hyperlipidemia, at the Endocrine Societys Annual Meeting
10. Encouraging Clinical Activity of GSKs Novel Cancer Immunotherapeutic Confirmed in Phase II Study in Patients with Most Common Form of Lung Cancer
11. Clinical Data on ARIADs Novel mTOR Inhibitor, AP23573, To Be Presented at the ASCO Annual Meeting
Post Your Comments:
(Date:10/25/2014)... DUBLIN , Oct. 24, 2014 ... "Dental Equipment Market Current Trends, Opportunities - Global ... In this report, the global dental equipment ... geography. The dental systems and equipment market is expected ... equipment market during the forecast period (2014 to 2019). ...
(Date:10/25/2014)... , Oct. 24, 2014  America,s future engineers ... robotic competition at the  Medical Design and Manufacturing ... 29-30 th at the Minneapolis ... local student built robots from the "For Inspiration ... FIRST students and mentors will offer information to ...
(Date:10/25/2014)... , October 24, 2014 ... the addition of the "Global and Chinese ... their offering.      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ... Report 2014 is a professional and in-depth study ... industry with a focus on the Chinese situation. ...
Breaking Medicine Technology:Dental Equipment Market Current Trends, Opportunities - Global Forecast to 2019 2Dental Equipment Market Current Trends, Opportunities - Global Forecast to 2019 3Local robotics teams compete - a "FIRST" at next week's MD&M Minneapolis- October 29-30th at the Minneapolis Convention Center 2Local robotics teams compete - a "FIRST" at next week's MD&M Minneapolis- October 29-30th at the Minneapolis Convention Center 3Global and Chinese Hemodialysis Concentrates Industry Report 2014 2Global and Chinese Hemodialysis Concentrates Industry Report 2014 3
... Quark siRNAs Examined Alone and in Combination ... Quark Pharmaceuticals, Inc., a,development-stage pharmaceutical company ... today announced that the,journal Cancer Research published ... target gene against non-small cell lung cancer ...
... Prophylaxis Treatment with Kogenate FS Reduces the,Risk of ... No Pre-Existing,Joint Damage, BERKELEY, Calif., Oct. 10 ... Food and Drug Administration (FDA) has,approved routine prophylaxis ... frequency of bleeding episodes and the risk of,joint ...
Cached Medicine Technology:Quark Pharmaceuticals Announces Publication of Study on Use of siRNA against Proprietary Target for Inhibiting Tumor Growth and Sensitization of Cancer Cells to Chemotherapy 2Quark Pharmaceuticals Announces Publication of Study on Use of siRNA against Proprietary Target for Inhibiting Tumor Growth and Sensitization of Cancer Cells to Chemotherapy 3Quark Pharmaceuticals Announces Publication of Study on Use of siRNA against Proprietary Target for Inhibiting Tumor Growth and Sensitization of Cancer Cells to Chemotherapy 4FDA Approves Bayer HealthCare's Kogenate(R) FS Treatment for Routine Prophylaxis in Children with Hemophilia A 2FDA Approves Bayer HealthCare's Kogenate(R) FS Treatment for Routine Prophylaxis in Children with Hemophilia A 3FDA Approves Bayer HealthCare's Kogenate(R) FS Treatment for Routine Prophylaxis in Children with Hemophilia A 4FDA Approves Bayer HealthCare's Kogenate(R) FS Treatment for Routine Prophylaxis in Children with Hemophilia A 5
(Date:10/25/2014)... -- A large influx of international aid is needed, ... of thousands of deaths from the widening Ebola crisis, ... Using a specially designed mathematical model, the researchers looked ... one densely populated county of hard-hit Liberia -- Montserrado ... The researchers said that if international aid isn,t delivered ...
(Date:10/25/2014)... Oct. 24, 2014 (HealthDay News) -- October,s shorter, darker ... seasonal affective disorder, according to an expert. ... may feel overly tired, lack motivation and even have ... can lead to suicide, said Dr. Angelos Halaris, a ... at Loyola University Chicago Stitch School of Medicine. ...
(Date:10/22/2014)... On October 22, CBS will air an ... both fictional and real. The Charles E Holman ... to advocacy and philanthropy in the battle against Morgellons ... to impart truth and clarity about this misunderstood and ... misconceptions about Morgellons Disease (MD) and most ...
(Date:10/22/2014)... (PRWEB) October 22, 2014 For Dr. Iris ... make money; it’s an extension of her life’s mission. Her ... venture as the owner of FirstLight HomeCare, make it clear ... important to me that my work makes a difference in ... an entrepreneurial spirit, so after much research, I felt ready ...
(Date:10/22/2014)... 2014 Shriners Hospitals for Children® and ... the current location of Shriners Hospitals for Children - ... from the University of Kentucky Albert B. Chandler Hospital. ... center, owned and operated by Shriners Hospitals for Children, ... children and their families well into the future. , ...
Breaking Medicine News(10 mins):Health News:Experts Predict 'Catastrophic' Ebola Epidemic in West Africa if Aid Delayed 2Health News:Dark Days Here for Folks With Seasonal Depression 2Health News:CBS’ Criminal Minds takes aim at skin disease with Morgellons in the Mix 2Health News:CBS’ Criminal Minds takes aim at skin disease with Morgellons in the Mix 3Health News:Dr. Iris Hunter to Host Grand Opening of FirstLight HomeCare Tomorrow 2Health News:Shriners Hospitals for Children - Lexington Announces Plan to Build New $47 Million Facility 2Health News:Shriners Hospitals for Children - Lexington Announces Plan to Build New $47 Million Facility 3
... 26 John Williams,a shrimp fisherman and executive ... the House Subcommittee on Oversight and,Investigations of the ... criticized the Food and Drug Administration,s,(FDA) reliance on ... legislative actions., "On behalf of the U.S. ...
... Customers and ... Private Insurance Corporations, OAKLAND, Calif., Feb. 26 ... organized by the California,Nurses Association/National Nurses Organizing Committee that ... a,9/11 rescue worker; Donna Smith, who has recently joined ...
... Settlement on Outstanding Disputes, SPOKANE, Wash., Feb. ... Sandpoint, Idaho reached settlement on four,outstanding disputes. The ... Spokane, Washington., "This settlement is very important ... capably despite management,s refusal to negotiate a fair,contract," ...
... entertains sports world, KANSAS CITY, Mo., Feb. ... with Kansas City roots. A team of college ... premier,community for all athletes, fans, coaches and professionals., ... have a positive impact,on the entire athletic community," ...
... ARJO, Inc. announces the release,of two new lifts, and ... a unique open, twin mast design, and the SARA ... Twin has twin masts, which improve stability and weight,distribution, ... design.,All powered functions, including Powered DPS (Dynamic Positioning System),are ...
... of the Board of Directors; Daniel ... Operating Officer -, EXTON, Pa., Feb. 26 ViroPharma Incorporated,(Nasdaq: ... J.,Milano will succeed Michel de Rosen as president and chief executive,officer ... directors. Mr.,de Rosen, who has led the company as president and ...
Cached Medicine News:Health News:Testimony to Congress Denounces FDA Reliance on Self-Policing 2Health News:Michael Moore Defends 9/11 Rescue Workers and Criticizes Insurance Industry on California Nurses Association Press Call 2Health News:Nurses Convince Hospital to Return to Bargaining Table 2Health News:AthletixNation.com Launches Sports Website and Community Programs 2Health News:Vincent J. Milano to Succeed Michel de Rosen as President and Chief Executive Officer of ViroPharma 2Health News:Vincent J. Milano to Succeed Michel de Rosen as President and Chief Executive Officer of ViroPharma 3
Synchron CX3 Delta is a critical care clinical system, providing unparalleled testing speed for the most frequently ordered chemistries-Glucose, BUN, Creatinine, Sodium, Potassium Chloride, CO2 Calci...
Iron (Total/Ferene). Storage temp: 15 - 30 C. Linearity: 0 - 500 ug/dl. Expected values: from males 60 - 160 ug/dl, from females 43 - 140 ug/dl. Available with Calibrator and Number of test are 120....
For the quantitative determination of iron, total iron-binding capacity in human serum....
HDL Cholesterol, liquid....
Medicine Products: